Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS8IFC)

• Drug Name: Sorafenib Drug Info
• Synonyms: Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[1]
Carcinoma	2A00-2F9Z	Approved	[1]
Clear cell renal carcinoma		Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Medullary thyroid gland carcinoma		Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Renal cell carcinoma	2C90	Approved	[2]
Thyroid cancer	2D10	Approved	[1]
Hepatocellular carcinoma	2C12.02	Phase 3	[2]
Myelodysplastic syndrome	2A37	Phase 2	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 216239
  ChEBI ID: CHEBI:50924
  CAS Number: CAS 284461-73-0
  TTD Drug ID: DMS8IFC
  VARIDT Drug ID: DR00304
  INTEDE Drug ID: DR1500
  ACDINA Drug ID: D00635

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[21]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[22]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[23]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[23]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[24]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[25]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[26]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[27]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[28]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[29]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[30]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[31]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[32]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[27]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[28]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[33]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[34]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[36]
PMID25656651-Compound-21a	DMCKAON	N. A.	N. A.	Patented	[37]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[38]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[39]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[40]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[21]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[41]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[42]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[43]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[41]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[44]
Nitroglycerin	DMQ2491	Angina pectoris	BA40	Approved	[45]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[232]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[233]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[234]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[235]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[236]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[237]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[238]
Selenium	DM25CGV	N. A.	N. A.	Approved	[239]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[240]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[46]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[23]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[47]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[48]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[21]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[24]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[49]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[50]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[51]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[52]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[531]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[532]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[533]
Haloperidol	DM96SE0	Delirium		Approved	[534]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[534]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[308]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[535]

Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[53]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[54]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[55]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[56]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[57]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[58]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[59]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[60]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[61]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[62]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[63]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[65]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[66]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[65]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[65]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[67]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[65]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[68]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[69]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[70]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[71]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[72]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[73]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[74]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[75]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[76]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[75]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[77]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[78]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[80]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[81]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[82]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[83]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[84]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[85]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[82]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[86]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[87]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[88]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[89]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[90]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[63]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[91]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[92]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[93]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[94]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[63]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[95]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[96]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[97]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[98]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[83]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[85]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[99]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[85]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[100]

Drug(s) Transported By RalBP1-associated Eps domain-containing protein 2 (RALBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[5]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[101]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[102]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[103]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[104]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[105]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[106]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[107]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[108]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[102]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[109]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[110]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[111]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[112]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[113]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[114]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[107]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[116]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[117]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[118]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[119]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[120]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[121]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[123]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[125]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[126]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[127]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[128]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[13]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[129]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[130]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[13]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[13]
Metronidazole	DMTIVEN	Abscess		Approved	[131]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[132]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[110]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[133]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[133]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[129]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[134]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[135]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[133]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[136]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[137]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[138]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[144]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[145]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[144]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[145]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[146]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[144]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[144]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[144]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[147]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[148]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[139]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[141]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[109]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[109]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[109]
Haloperidol	DM96SE0	Delirium		Approved	[109]
Naproxen	DMZ5RGV	Bursitis		Approved	[143]

Drug(s) Affected By ATP-binding cassette sub-family C member 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[149]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[150]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[151]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[152]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[153]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[154]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[155]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[156]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[157]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]

Drug(s) Affected By Mast/stem cell growth factor receptor Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[159]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[163]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[164]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[165]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[166]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[167]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[168]

Drug(s) Affected By NF-kappa-B inhibitor alpha (NFKBIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fructose	DM43AN2	Vomiting	MD90	Approved	[169]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[170]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[172]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[174]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[175]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[176]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[177]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]

Drug(s) Affected By DNA damage-inducible transcript 3 protein (DDIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Triacetin	DM0AEPG	Onychomycosis	EE12.1	Approved	[180]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[182]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[184]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[185]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[186]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[187]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]

Drug(s) Affected By DNA damage-inducible transcript 4 protein (DDIT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[188]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[191]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[193]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[195]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[196]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[197]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[197]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[198]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[196]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[197]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[199]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[196]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[200]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[196]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[201]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[202]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[203]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[204]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[205]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[206]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[207]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[208]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[209]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[210]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[211]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[202]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[212]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[213]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[214]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[201]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[169]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[204]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[205]

Drug(s) Affected By Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[215]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[216]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[218]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[219]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[220]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[221]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[222]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[221]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[223]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[224]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[225]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[227]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[215]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[228]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[229]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[230]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[231]

Drug(s) Affected By GTPase NRas (NRAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[241]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[242]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[243]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[244]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[248]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[220]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[221]

Drug(s) Affected By Insulin-like growth factor 1 receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[249]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[250]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[251]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[252]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[254]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[255]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[257]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[258]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[259]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[260]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[261]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[169]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[262]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[263]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[264]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[204]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[265]

Drug(s) Affected By Protein kinase C alpha type (PRKCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[266]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[267]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[270]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[272]

Drug(s) Affected By Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[273]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[274]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[275]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[276]
Selenium	DM25CGV	N. A.	N. A.	Approved	[277]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[278]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[279]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[281]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[282]

Drug(s) Affected By Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[285]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[286]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[287]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[288]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]

Drug(s) Affected By Serine/threonine-protein kinase mTOR (MTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[289]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[290]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[291]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[292]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[293]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[294]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[295]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[296]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[297]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[298]

Drug(s) Affected By Cyclin-dependent kinase 9 (CDK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[300]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[301]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[302]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[303]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[304]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]

Drug(s) Affected By Growth factor receptor-bound protein 2 (GRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[238]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[305]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[306]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[243]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[307]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[308]

Drug(s) Affected By E3 ubiquitin-protein ligase Mdm2 (MDM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Flucytosine	DM13VTW	Cryptococcal meningitis		Approved	[309]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[309]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[310]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[312]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[313]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[193]
Amifostine	DM5FL14	Mucositis	CA00	Approved	[314]

Drug(s) Affected By Interferon regulatory factor 5 (IRF5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[315]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[220]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[316]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[283]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[317]
Diphenylpyraline	DMW4X37	Allergic rhinitis	CA08.0	Approved	[318]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[319]

Drug(s) Affected By Hypoxia-inducible factor 1-alpha (HIF1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[320]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[321]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[322]
Triamterene	DM2HU9I	Congestive heart failure	BD10	Approved	[322]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[323]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[324]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[325]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[326]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[327]

Drug(s) Affected By Serine/threonine-protein kinase PLK3 (PLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[328]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[257]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[257]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[330]

Drug(s) Affected By Serine/threonine-protein kinase PLK2 (PLK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[332]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[328]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[333]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[248]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[334]

Drug(s) Affected By Histone deacetylase 6 (HDAC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[335]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[336]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[337]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[338]
Bortezomib	DMNO38U	Leukemia		Approved	[339]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[340]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[340]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[189]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[341]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[342]
Selenium	DM25CGV	N. A.	N. A.	Approved	[343]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[189]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[344]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[315]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[344]

Drug(s) Affected By CASP8 and FADD-like apoptosis regulator (CFLAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[345]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[346]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[347]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[348]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[349]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[231]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[350]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[351]

Drug(s) Affected By Bcl-2-like protein 11 (BCL2L11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[352]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[353]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[354]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[355]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[356]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[357]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[358]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[359]

Drug(s) Affected By Zinc finger protein SNAI2 (SNAI2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[360]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[361]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[362]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[333]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]

Drug(s) Affected By E3 ubiquitin-protein ligase parkin (PRKN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emtricitabine	DMBMUWZ	Hepatitis virus infection	1E50-1E51	Approved	[363]
Tubocurarine	DMBZIVP	Anaesthesia	9A78.6	Approved	[364]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[365]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[366]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[367]
Methamphetamine	DMPM4SK	Anxiety		Approved	[368]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[369]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[303]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[364]

Drug(s) Affected By Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[262]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[370]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[371]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[362]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[328]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]

Drug(s) Affected By Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[342]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[187]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[372]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[373]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[374]

Drug(s) Affected By Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[273]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[375]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[376]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[377]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[378]

Drug(s) Affected By Apoptosis-inducing factor 1, mitochondrial (AIFM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[238]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[379]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[354]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[380]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[381]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[382]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[383]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]

Drug(s) Affected By Tyrosine-protein kinase ABL1 (ABL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[169]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[169]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[384]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[385]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[386]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[387]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[388]

Drug(s) Affected By Urokinase-type plasminogen activator (PLAU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[389]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[315]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[390]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[389]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[391]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[392]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[393]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[169]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[290]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[394]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[395]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[396]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[397]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[398]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[399]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[400]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[172]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[401]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[402]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[403]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[402]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[404]
Selenium	DM25CGV	N. A.	N. A.	Approved	[405]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[406]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[407]

Drug(s) Affected By RAF proto-oncogene serine/threonine-protein kinase (RAF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[409]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[410]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[411]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[412]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[413]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[414]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[415]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[243]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[416]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[417]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[418]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[419]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[420]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[421]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[422]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[423]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[424]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[425]

Drug(s) Affected By Transcription factor Jun (JUN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[426]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[427]
Fructose	DM43AN2	Vomiting	MD90	Approved	[169]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[428]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[429]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[430]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[431]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[432]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[433]

Drug(s) Affected By Tyrosine-protein kinase Lck (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[434]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[435]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[380]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[436]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[437]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[438]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[439]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[440]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[441]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[442]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[443]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[444]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[353]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[445]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[446]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[447]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[282]

Drug(s) Affected By Eukaryotic translation initiation factor 4E (EIF4E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[448]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[449]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[380]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[450]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[451]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[452]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[453]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[452]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[220]

Drug(s) Affected By Proto-oncogene tyrosine-protein kinase receptor Ret (RET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[454]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[455]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[454]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[456]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[455]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[454]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[457]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[286]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]

Drug(s) Affected By High mobility group protein B1 (HMGB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[458]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[401]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[459]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[362]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[460]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[262]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[461]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[462]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[463]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[278]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[463]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[464]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[465]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[466]

Drug(s) Affected By Breakpoint cluster region protein (BCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[282]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[467]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[468]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[469]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[470]
Bortezomib	DMNO38U	Leukemia		Approved	[219]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[220]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[471]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[472]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[473]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[474]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[475]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[476]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[473]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[477]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[474]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[473]

Drug(s) Affected By Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[478]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[479]
Selenium	DM25CGV	N. A.	N. A.	Approved	[277]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[480]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[281]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[481]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[282]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]

Drug(s) Affected By Cadherin-1 (CDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[345]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[360]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[482]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[483]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[484]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[485]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[486]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]

Drug(s) Affected By Proto-oncogene tyrosine-protein kinase Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[487]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[488]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[400]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[489]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[490]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[491]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[492]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[492]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]

Drug(s) Affected By Serine/threonine-protein kinase B-raf (BRAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[493]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[380]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[297]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[494]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[221]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[495]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[236]

Drug(s) Affected By Platelet-derived growth factor receptor alpha (PDGFRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Vismodegib	DM5IXKQ	Basal cell carcinoma	2C32	Approved	[496]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[497]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[333]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[498]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[167]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[499]

Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-4 (ATF4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[215]
Pyrazinamide	DM4IF32	Meningeal tuberculosis		Approved	[501]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[502]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[503]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[504]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[505]

Drug(s) Affected By Ribosomal protein S6 kinase beta-1 (RPS6KB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[506]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[291]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[292]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[507]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[353]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[508]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[327]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[434]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[509]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[510]

Drug(s) Affected By Alanine aminotransferase 1 (GPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[169]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[511]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[512]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[169]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[169]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[169]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[15]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[513]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[15]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[15]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[514]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[515]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[265]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[516]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[233]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[444]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[517]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[294]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[518]

Drug(s) Affected By G1/S-specific cyclin-D2 (CCND2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[238]
Selenium	DM25CGV	N. A.	N. A.	Approved	[277]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[282]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[519]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[520]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[521]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[307]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[333]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]

Drug(s) Affected By G1/S-specific cyclin-D3 (CCND3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[273]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[233]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[282]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[522]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[523]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[520]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[524]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[525]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[328]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[526]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[527]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[528]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[265]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[529]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[507]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[530]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[251]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[294]

Drug(s) Affected By Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[536]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[537]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[411]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[538]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[436]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[539]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[503]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]

Drug(s) Affected By Signal transducer and activator of transcription 3 (STAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[169]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[540]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[541]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[542]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[543]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[315]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[544]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[545]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[489]

Drug(s) Affected By Signal transducer and activator of transcription 5A (STAT5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[400]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[546]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[547]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[548]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[549]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[550]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[551]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[552]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[553]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[554]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[555]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[556]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[557]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[558]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[170]

Drug(s) Affected By Mitogen-activated protein kinase 8 (MAPK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[559]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[428]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[560]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[432]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[349]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[561]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[562]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[432]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[563]

Drug(s) Affected By Mitogen-activated protein kinase 9 (MAPK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[428]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[432]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[564]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[565]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[432]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[566]
Sorbitol	DMAN0DE	Constipation	DD91.1	Approved	[567]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]

Drug(s) Affected By Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[568]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[569]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[308]
Indomethacin	DMSC4A7	Bursitis		Approved	[570]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[571]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[568]

Drug(s) Affected By Crk-like protein (CRKL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[386]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[572]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[573]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[222]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[303]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[574]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[575]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[576]
PMID25656651-Compound-5	DMAI95U	Chronic myeloid leukaemia	2A20	Patented	[577]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[442]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[233]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[578]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[564]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[579]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[235]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[580]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[581]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[582]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[583]

Drug(s) Affected By CCAAT/enhancer-binding protein delta (CEBPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[584]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[585]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[374]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[256]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[256]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[586]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]

Drug(s) Affected By Glycogen synthase kinase-3 beta (GSK3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[587]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[443]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[588]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[589]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[590]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[349]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[591]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[502]

Drug(s) Affected By Tumor necrosis factor ligand superfamily member 10 (TNFSF10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[182]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[345]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[592]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[593]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[421]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[449]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[594]

Drug(s) Affected By Stanniocalcin-1 (STC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[595]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[148]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[362]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[328]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[359]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[596]

Drug(s) Affected By Caspase-7 (CASP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[597]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[598]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[599]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[600]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[600]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[568]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[601]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[602]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[603]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[604]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[262]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[264]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[605]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[606]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[607]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[608]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[609]

Drug(s) Affected By Gasdermin-D (GSDMD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[610]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[459]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[611]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[612]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[248]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[613]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[614]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[615]

Drug(s) Affected By Sestrin-2 (SESN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[403]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[187]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[616]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[193]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[616]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[195]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[179]

Drug(s) Affected By Small ribosomal subunit protein eS6 (RPS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[617]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[315]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[618]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[509]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[619]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[620]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[621]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[622]
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[526]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[623]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[461]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[605]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[624]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[599]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[400]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[625]
Pefloxacin	DM49IGF	Gonococcal urethritis	1A70.0Y	Approved	[626]

Drug(s) Affected By Cyclin-dependent kinase 6 (CDK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[479]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[627]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[443]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[445]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[315]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[349]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[522]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[162]

Drug(s) Affected By Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[408]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[628]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[629]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[563]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[194]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[412]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[415]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[308]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[258]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[170]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[262]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[263]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[345]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[605]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[444]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[630]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[278]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[528]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[631]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[632]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[309]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[348]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[349]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[421]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[633]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[634]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[635]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[636]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[636]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[637]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[638]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[639]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[640]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[636]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 3 (BIRC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[641]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[170]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[616]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[642]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[643]

Drug(s) Affected By Sequestosome-1 (SQSTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[290]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[291]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[644]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[188]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[645]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[215]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[331]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[584]

Drug(s) Affected By Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[646]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[294]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[481]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[449]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[647]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[372]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[621]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[451]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[164]

Drug(s) Affected By Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[179]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[370]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[648]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[649]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[650]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[651]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[652]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[193]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[653]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[654]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[655]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[656]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[657]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Selenium	DM25CGV	N. A.	N. A.	Approved	[500]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[608]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[400]

Drug(s) Affected By Mitogen-activated protein kinase 14 (MAPK14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[658]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[659]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[660]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[661]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[434]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[524]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[563]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[662]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[663]

Drug(s) Affected By Bcl-2 homologous antagonist/killer (BAK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[664]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[665]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[311]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[666]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Levamisole	DM5EN79	Parasitic infection	1D0Y-1G2Z	Approved	[667]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[668]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[669]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[670]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[417]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[184]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[671]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[672]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[673]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[674]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[675]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[676]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[677]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[678]

Drug(s) Affected By Bcl2-associated agonist of cell death (BAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[679]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[170]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[171]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[680]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[681]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[682]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[268]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[683]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[357]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[412]

Drug(s) Affected By Docking protein 1 (DOK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[359]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[684]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[685]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[316]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[303]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[500]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[686]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[687]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[537]

Drug(s) Affected By Serine/threonine-protein kinase PINK1, mitochondrial (PINK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[688]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[689]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[286]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[689]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[365]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[690]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[691]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[248]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[692]

Drug(s) Affected By Eukaryotic translation initiation factor 2A (EIF2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[182]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[537]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[434]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[693]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[694]
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[695]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[696]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[383]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]

Drug(s) Affected By Autophagy protein 5 (ATG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[292]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[697]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[698]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[699]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[700]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[670]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[701]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[258]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[702]

Drug(s) Affected By Transcription factor SOX-17 (SOX17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[703]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[703]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[703]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[703]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[703]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[703]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[704]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[167]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[703]
Ziprasidone	DMM58JY	Bipolar disorder	6A60	Approved	[703]

Drug(s) Affected By Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[290]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[503]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[705]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[164]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[706]
Atazanavir	DMSYRBX	Human immunodeficiency virus infection	1C62	Approved	[503]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[707]

Drug(s) Affected By Diablo IAP-binding mitochondrial protein (DIABLO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[659]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[238]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[226]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[649]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[708]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[709]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[328]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[387]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[247]

Drug(s) Affected By Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[710]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[181]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[183]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[711]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[183]
Pyrazinamide	DM4IF32	Meningeal tuberculosis		Approved	[501]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[502]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[504]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM62 (TRIM62)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[372]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[271]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[217]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[707]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[303]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[304]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[712]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[615]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[687]

Drug(s) Affected By Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[204]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[345]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[713]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[714]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[651]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[345]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[715]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[351]

Drug(s) Affected By ATP-binding cassette sub-family C member 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[157]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[716]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[717]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[718]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[719]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[720]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[283]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[721]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[722]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[176]

Drug(s) Affected By Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[299]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[723]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[724]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[725]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[725]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[705]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[726]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[727]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[728]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[729]

Drug(s) Affected By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[730]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[731]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[153]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[732]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[733]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[734]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[156]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[735]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[736]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[736]

Drug(s) Affected By Receptor-type tyrosine-protein kinase FLT3 (FLT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[737]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[738]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[531]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[739]
Venetoclax	DM8I94Y	Chronic lymphocytic leukaemia	2A82.0	Approved	[740]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[741]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[168]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[742]

Drug(s) Affected By Na(+)/citrate cotransporter (SLC13A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[268]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[743]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[744]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[359]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[245]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[246]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[220]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[745]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[3]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Modulator	[4]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Modulator	[4]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Modulator	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
RalBP1-associated Eps domain-containing protein 2 (RALBP1)	DTYEM9B	REPS2_HUMAN	Substrate	[5]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[6]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[7]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[11]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[14]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Protein Interaction/Cellular Processes	[15]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Protein Interaction/Cellular Processes	[16]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[17]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Protein Interaction/Cellular Processes	[16]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Drug Response	[18]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Drug Response	[18]
Autophagy protein 5 (ATG5)	OT4T5SMS	ATG5_HUMAN	Gene/Protein Processing	[19]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Gene/Protein Processing	[20]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[17]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Gene/Protein Processing	[16]

References

• [1] Sorafenib FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
• [3] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [4] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [5] Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
• [6] Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
• [7] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [8] Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
• [9] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [10] Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
• [11] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [12] Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
• [13] Drug Interactions Flockhart Table
• [14] Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
• [15] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [16] Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
• [17] Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
• [18] The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
• [19] Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
• [20] The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
• [21] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [22] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [24] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [25] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [27] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [28] National Cancer Institute Drug Dictionary (drug id 452042).
• [29] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [30] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [31] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [32] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [33] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [34] Company report (Neuronova)
• [35] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [36] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [37] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [38] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [39] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [40] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [42] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [43] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [44] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [45] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [46] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [47] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [48] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [49] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [50] Clinical pipeline report, company report or official report of Exelixis (2011).
• [51] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [52] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [53] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [54] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [55] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [56] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [57] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [58] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [59] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [60] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [61] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [62] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [63] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [64] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [65] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [66] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [67] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [68] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [69] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [70] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [71] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [72] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [73] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [74] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [75] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [76] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [77] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [78] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [79] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [80] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [81] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [82] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [83] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [84] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [85] FDA Drug Development and Drug Interactions
• [86] Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
• [87] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [88] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [89] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [90] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [91] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [92] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [93] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [94] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [95] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [96] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [97] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [98] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [99] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [100] Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
• [101] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [102] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [103] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [104] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [105] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [106] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [107] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [108] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [109] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [110] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [111] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [112] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [113] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [114] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [115] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [116] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [117] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [118] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [119] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [120] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [121] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [122] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [123] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [124] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [125] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [126] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [127] 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
• [128] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [129] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [130] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [131] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [132] Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
• [133] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [134] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [135] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [136] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [137] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [138] Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
• [139] Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
• [140] Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
• [141] The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
• [142] The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
• [143] S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
• [144] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [145] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [146] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [147] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [148] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [149] Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
• [150] Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
• [151] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [152] Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
• [153] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [154] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [155] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [156] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [157] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [158] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [159] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [160] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [161] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [162] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [163] [Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):613-6. doi: 10.7534/j.issn.1009-2137.2013.03.015.
• [164] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [165] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [166] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [167] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [168] Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010 Feb 15;16(4):1149-58. doi: 10.1158/1078-0432.CCR-09-2416. Epub 2010 Feb 9.
• [169] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [170] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [171] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [172] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [173] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [174] Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
• [175] Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001 Dec 21;276(51):47828-33. doi: 10.1074/jbc.M106103200. Epub 2001 Oct 8.
• [176] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [177] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [178] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [179] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [180] Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2 pathway. Toxicology. 2011 Sep 5;287(1-3):105-12. doi: 10.1016/j.tox.2011.06.005. Epub 2011 Jun 15.
• [181] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [182] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [183] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [184] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [185] High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
• [186] Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
• [187] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [188] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [189] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [190] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [191] Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells. BMB Rep. 2010 Sep;43(9):599-603. doi: 10.5483/BMBRep.2010.43.9.599.
• [192] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [193] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [194] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [195] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [196] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [197] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [198] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [199] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [200] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [201] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [202] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [203] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [204] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [205] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [206] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [207] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [208] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [209] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [210] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [211] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [212] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [213] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [214] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [215] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [216] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [217] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [218] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [219] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [220] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [221] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [222] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [223] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [224] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [225] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [226] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [227] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [228] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [229] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [230] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [231] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [232] Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
• [233] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [234] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [235] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [236] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [237] Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
• [238] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [239] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [240] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [241] Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer. 2000 Feb 1;85(3):438-45.
• [242] Poly(ADP-ribosyl)ation enhances H-RAS protein stability and causes abnormal cell cycle progression in human TK6 lymphoblastoid cells treated with hydroquinone. Chem Biol Interact. 2015 Aug 5;238:1-8. doi: 10.1016/j.cbi.2015.05.019. Epub 2015 Jun 3.
• [243] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [244] Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol. 2005 Sep;130(6):912-25. doi: 10.1111/j.1365-2141.2005.05696.x.
• [245] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [246] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [247] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [248] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [249] Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):219-30. doi: 10.1016/j.jsbmb.2009.09.018. Epub 2009 Oct 6.
• [250] Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007 May 1;13(9):2795-803. doi: 10.1158/1078-0432.CCR-06-2077.
• [251] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [252] Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2008 Jul 25;372(2):356-61. doi: 10.1016/j.bbrc.2008.05.043. Epub 2008 May 19.
• [253] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [254] Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009 Dec;100(12):2459-64.
• [255] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [256] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [257] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [258] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [259] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [260] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [261] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [262] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [263] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [264] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [265] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [266] Activation of ERK1/2 by protein kinase C-alpha in response to hydrogen peroxide-induced cell death in human gingival fibroblasts. Toxicol In Vitro. 2010 Feb;24(1):319-26. doi: 10.1016/j.tiv.2009.08.007. Epub 2009 Aug 21.
• [267] Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep. 2015 Sep;42(9):1419-29. doi: 10.1007/s11033-015-3921-7. Epub 2015 Aug 27.
• [268] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [269] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [270] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [271] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [272] The vanilloid capsaicin induces IL-6 secretion in prostate PC-3 cancer cells. Cytokine. 2011 Jun;54(3):330-7. doi: 10.1016/j.cyto.2011.03.010. Epub 2011 Apr 6.
• [273] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [274] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [275] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [276] Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence. Int J Biochem Cell Biol. 2003 Feb;35(2):246-54. doi: 10.1016/s1357-2725(02)00129-2.
• [277] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [278] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [279] Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
• [280] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [281] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [282] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [283] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [284] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [285] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.
• [286] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [287] Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1. Chem Biol Interact. 2020 Feb 1;317:108939. doi: 10.1016/j.cbi.2020.108939. Epub 2020 Jan 13.
• [288] Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.
• [289] eIF4E is a critical regulator of human papillomavirus (HPV)-immortalized cervical epithelial (H8) cell growth induced by nicotine. Toxicology. 2019 May 1;419:1-10. doi: 10.1016/j.tox.2019.02.017. Epub 2019 Mar 2.
• [290] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [291] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [292] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [293] Repression of Kisspeptin1 weakens hydrogen peroxide-caused injury in HTR8 cells via adjusting PI3K/AKT/mTOR pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22461. doi: 10.1002/jbt.22461. Epub 2020 Feb 11.
• [294] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [295] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [296] Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One. 2012;7(10):e47516. doi: 10.1371/journal.pone.0047516. Epub 2012 Oct 18.
• [297] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [298] Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
• [299] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [300] Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biol Ther. 2005 Mar;4(3):277-81. doi: 10.4161/cbt.4.3.1497. Epub 2005 Mar 20.
• [301] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [302] Elucidating progesterone effects in breast cancer: cross talk with PDGF signaling pathway in smooth muscle cell. J Cell Biochem. 2007 Jan 1;100(1):174-83. doi: 10.1002/jcb.21045.
• [303] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [304] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [305] Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells. BMC Complement Altern Med. 2016 Aug 11;16(1):281. doi: 10.1186/s12906-016-1267-x.
• [306] Proteomic analysis to identify the cellular responses induced by hydroquinone in human embryonic lung fibroblasts. Toxicol Mech Methods. 2006;16(1):1-6. doi: 10.1080/15376520500191797.
• [307] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct. 2005;30(1):1-6. doi: 10.1247/csf.30.1.
• [308] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [309] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [310] In vitro antioxidant and antigenotoxic potentials of 3,5-O-di-galloylquinic acid extracted from Myrtus communis leaves and modulation of cell gene expression by H2O2. J Appl Toxicol. 2012 May;32(5):333-41.
• [311] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [312] HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 2005 Mar;19(3):476-8. doi: 10.1096/fj.04-2745fje. Epub 2004 Dec 29.
• [313] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [314] Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther. 2003 Sep;2(9):893-900.
• [315] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [316] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [317] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [318] Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
• [319] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [320] Cannabidiol disrupts apoptosis, autophagy and invasion processes of placental trophoblasts. Arch Toxicol. 2021 Oct;95(10):3393-3406. doi: 10.1007/s00204-021-03122-z. Epub 2021 Jul 24.
• [321] AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells. Carcinogenesis. 2004 Dec;25(12):2497-507. doi: 10.1093/carcin/bgh253. Epub 2004 Aug 5.
• [322] Identification of chemical compounds that induce HIF-1alpha activity. Toxicol Sci. 2009 Nov;112(1):153-63.
• [323] NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
• [324] Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008 Mar;51(3):267-73. doi: 10.1097/FJC.0b013e3181624b44.
• [325] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [326] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [327] SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80. doi: 10.1016/j.bbrc.2004.09.082.
• [328] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [329] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [330] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [331] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [332] The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007 Apr;6(4):1300-9.
• [333] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [334] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [335] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [336] Estrogen down regulates COMT transcription via promoter DNA methylation in human breast cancer cells. Toxicol Appl Pharmacol. 2019 Mar 15;367:12-22.
• [337] Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. Anticancer Drugs. 2005 Jul;16(6):635-43. doi: 10.1097/00001813-200507000-00008.
• [338] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [339] Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006 Apr 1;66(7):3773-81. doi: 10.1158/0008-5472.CAN-05-2961.
• [340] ERR contributes to HDAC6-induced chemoresistance of osteosarcoma cells. Cell Biol Toxicol. 2023 Jun;39(3):813-825. doi: 10.1007/s10565-021-09651-8. Epub 2021 Sep 15.
• [341] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [342] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [343] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [344] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [345] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [346] PGK1 induction by a hydrogen peroxide treatment is suppressed by antioxidants in human colon carcinoma cells. Biosci Biotechnol Biochem. 2008 Jul;72(7):1799-808. doi: 10.1271/bbb.80079. Epub 2008 Jul 7.
• [347] Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001 Feb;7(2):407-14.
• [348] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [349] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [350] Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol. 2002 Jan;22(1):37-47. doi: 10.1023/a:1014256603539.
• [351] Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res. 2012 Dec 15;18(24):6690-701. doi: 10.1158/1078-0432.CCR-12-0770. Epub 2012 Oct 18.
• [352] Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther. 2007 Mar;6(3):1031-8. doi: 10.1158/1535-7163.MCT-06-0643. Epub 2007 Mar 5.
• [353] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [354] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [355] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [356] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [357] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [358] Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010 Feb;15(2):219-29. doi: 10.1007/s10495-009-0424-9.
• [359] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [360] Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H2O2-dependent Snail signaling. Free Radic Biol Med. 2012 Jul 1;53(1):44-50. doi: 10.1016/j.freeradbiomed.2012.04.031. Epub 2012 May 9.
• [361] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [362] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [363] Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
• [364] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [365] Silibinin inhibits ethanol- or acetaldehyde-induced ferroptosis in liver cell lines. Toxicol In Vitro. 2022 Aug;82:105388. doi: 10.1016/j.tiv.2022.105388. Epub 2022 May 18.
• [366] Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
• [367] Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci. 2006 Sep;24(5):1366-72. doi: 10.1111/j.1460-9568.2006.04998.x.
• [368] Involvement of C/EBP-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis. Toxicol Lett. 2019 Sep 15;312:11-21. doi: 10.1016/j.toxlet.2019.05.003. Epub 2019 May 3.
• [369] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [370] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [371] Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol. 2008 Jun;46(6):2042-53. doi: 10.1016/j.fct.2008.01.049. Epub 2008 Feb 7.
• [372] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [373] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [374] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [375] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [376] SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-B/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May 16;4(5):e635. doi: 10.1038/cddis.2013.159.
• [377] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [378] Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci. 2022 Sep 24;189(2):216-224. doi: 10.1093/toxsci/kfac073.
• [379] Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005 Sep 2;77(16):2059-70. doi: 10.1016/j.lfs.2005.04.021.
• [380] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [381] Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res. 2004 May 1;10(9):3179-88. doi: 10.1158/1078-0432.ccr-03-0309.
• [382] Clonidine Induces Apoptosis of Human Corneal Epithelial Cells through Death Receptors-Mediated, Mitochondria-Dependent Signaling Pathway. Toxicol Sci. 2017 Mar 1;156(1):252-260. doi: 10.1093/toxsci/kfw249.
• [383] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [384] Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology. 2006 Oct;131(4):1235-52. doi: 10.1053/j.gastro.2006.08.009.
• [385] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [386] Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood). 2013 Aug 1;238(8):932-42. doi: 10.1177/1535370213492689. Epub 2013 Jul 24.
• [387] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [388] Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009 Aug;30(8):1320-9. doi: 10.1093/carcin/bgp138. Epub 2009 Jun 5.
• [389] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [390] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [391] Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
• [392] Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
• [393] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [394] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [395] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [396] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [397] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [398] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [399] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [400] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [401] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [402] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [403] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [404] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [405] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [406] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [407] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [408] Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
• [409] Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009 May;21(5):1317-22. doi: 10.3892/or_00000357.
• [410] Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol. 2003 Mar;148(3):544-52. doi: 10.1046/j.1365-2133.2003.05174.x.
• [411] Regulation of genistein-induced differentiation in human acute myeloid leukaemia cells (HL60, NB4) Protein kinase modulation and reactive oxygen species generation. Biochem Pharmacol. 2009 Feb 1;77(3):384-96. doi: 10.1016/j.bcp.2008.10.035. Epub 2008 Nov 6.
• [412] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [413] Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol Lett. 2012 Mar 25;209(3):239-45. doi: 10.1016/j.toxlet.2011.12.020. Epub 2012 Jan 8.
• [414] Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 2003 Sep;15(9):851-9. doi: 10.1016/s0898-6568(03)00036-6.
• [415] Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 2010 Apr 15;9(8):1629-38. doi: 10.4161/cc.9.8.11487. Epub 2010 Apr 15.
• [416] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [417] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [418] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [419] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [420] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [421] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [422] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [423] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [424] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [425] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [426] High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3133-40.
• [427] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [428] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [429] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [430] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [431] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [432] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [433] [Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells]. Zhonghua Fu Chan Ke Za Zhi. 2014 Jul;49(7):531-5.
• [434] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [435] Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
• [436] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [437] Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
• [438] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [439] Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
• [440] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [441] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [442] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [443] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [444] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [445] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [446] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [447] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [448] Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2022 Jan 15;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.
• [449] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [450] Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.
• [451] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [452] The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
• [453] The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
• [454] Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
• [455] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [456] Hypotensive shock and angio-oedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values. J Intern Med. 2005 Oct;258(4):385-7. doi: 10.1111/j.1365-2796.2005.01547.x.
• [457] Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005 Feb 1;11(3):1336-41.
• [458] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [459] Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
• [460] Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells. Chem Biol Interact. 2021 May 1;340:109434. doi: 10.1016/j.cbi.2021.109434. Epub 2021 Mar 6.
• [461] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [462] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [463] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [464] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [465] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [466] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [467] AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
• [468] Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004 Sep 1;101(5):979-88. doi: 10.1002/cncr.20457.
• [469] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [470] Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Exp Hematol. 2009 Feb;37(2):206-14. doi: 10.1016/j.exphem.2008.10.013. Epub 2008 Dec 18.
• [471] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [472] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [473] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [474] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [475] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [476] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [477] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [478] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
• [479] In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
• [480] JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
• [481] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [482] Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci. 2010 Jul;72(7):869-74.
• [483] Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
• [484] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [485] Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009 Mar 13;380(3):614-9. doi: 10.1016/j.bbrc.2009.01.134. Epub 2009 Jan 27.
• [486] Regulation of epithelial cell morphology and functions approaching to more in vivo-like by modifying polyethylene glycol on polysulfone membranes. PLoS One. 2012;7(4):e36110.
• [487] SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057.
• [488] Selective activation of Src family kinases and JNK by low levels of chromium(VI). Toxicol Appl Pharmacol. 2003 Aug 1;190(3):214-23. doi: 10.1016/s0041-008x(03)00188-1.
• [489] Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.
• [490] Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
• [491] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
• [492] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [493] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [494] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [495] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.
• [496] Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.
• [497] Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer. 2005 May 1;103(9):1800-9. doi: 10.1002/cncr.20973.
• [498] The long-term impact of folic acid in pregnancy on offspring DNA methylation: follow-up of the Aberdeen Folic Acid Supplementation Trial (AFAST). Int J Epidemiol. 2018 Jun 1;47(3):928-937. doi: 10.1093/ije/dyy032.
• [499] Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol. 2008 Oct;36(10):1244-53. doi: 10.1016/j.exphem.2008.04.017. Epub 2008 Jul 10.
• [500] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [501] Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2-ATF4-CHOP pathway. Toxicology. 2017 Mar 1;378:65-75. doi: 10.1016/j.tox.2017.01.002. Epub 2017 Jan 4.
• [502] NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
• [503] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [504] Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway. Toxicol In Vitro. 2016 Oct;36:186-196. doi: 10.1016/j.tiv.2016.07.017. Epub 2016 Jul 26.
• [505] Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614-1626.
• [506] Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004 Apr 15;103(8):3138-47. doi: 10.1182/blood-2003-05-1543. Epub 2003 Dec 24.
• [507] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [508] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [509] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [510] Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15;63(22):7950-8.
• [511] Quercetin protected against isoniazide-induced HepG2 cell apoptosis by activating the SIRT1/ERK pathway. J Biochem Mol Toxicol. 2019 Sep;33(9):e22369. doi: 10.1002/jbt.22369. Epub 2019 Jul 23.
• [512] Drug-induced liver injury: Oltipraz and C2-ceramide intervene HNF-1/GSTA1 expression via JNK signaling pathway. J Appl Toxicol. 2021 Dec;41(12):2011-2020. doi: 10.1002/jat.4181. Epub 2021 May 6.
• [513] A Study of Gentianae Radix et Rhizoma Class Differences Based on Chemical Composition and Core Efficacy. Molecules. 2023 Oct 17;28(20):7132. doi: 10.3390/molecules28207132.
• [514] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [515] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [516] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [517] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [518] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [519] Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther. 2003 Jun;305(3):932-42. doi: 10.1124/jpet.103.049098. Epub 2003 Mar 20.
• [520] Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res. 2005 Jul 15;65(14):6476-83. doi: 10.1158/0008-5472.CAN-05-0370.
• [521] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [522] Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.
• [523] Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
• [524] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [525] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [526] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [527] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [528] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [529] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [530] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [531] SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 1;102(3):795-801. doi: 10.1182/blood-2002-10-3023. Epub 2003 Mar 20.
• [532] Low dosage of arsenic trioxide (As(2)O(3)) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis. J Biol Inorg Chem. 2018 Aug;23(6):939-947. doi: 10.1007/s00775-018-1595-z. Epub 2018 Jul 16.
• [533] Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004 Aug 15;64(16):5617-23. doi: 10.1158/0008-5472.CAN-03-3927.
• [534] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [535] Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 2006 Oct;20(12):2027-35. doi: 10.1096/fj.05-5404com.
• [536] trans-Resveratrol inhibits H2O2-induced adenocarcinoma gastric cells proliferation via inactivation of MEK1/2-ERK1/2-c-Jun signalling axis. Biochem Pharmacol. 2009 Feb 1;77(3):337-47. doi: 10.1016/j.bcp.2008.10.034. Epub 2008 Nov 6.
• [537] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [538] Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2+-dependent production of superoxide. Int J Cancer. 2001 May 15;92(4):518-26. doi: 10.1002/ijc.1220.
• [539] Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood. 2005 Feb 1;105(3):1214-21. doi: 10.1182/blood-2004-03-1182. Epub 2004 Sep 28.
• [540] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [541] Diesel exhaust particulate-induced activation of Stat3 requires activities of EGFR and Src in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L422-9. doi: 10.1152/ajplung.00204.2006. Epub 2006 Oct 6.
• [542] Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway. Toxicol Appl Pharmacol. 2020 Dec 1;408:115273. doi: 10.1016/j.taap.2020.115273. Epub 2020 Oct 6.
• [543] Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. doi: 10.1593/neo.06781.
• [544] Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009 Aug;33(2):107-14.
• [545] Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011 Jun 16;11:255. doi: 10.1186/1471-2407-11-255.
• [546] Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann Oncol. 2008 Aug;19(8):1488-1494. doi: 10.1093/annonc/mdn056. Epub 2008 Mar 17.
• [547] Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol. 2006 Apr;69(4):1486-91. doi: 10.1124/mol.105.018325. Epub 2006 Jan 24.
• [548] BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct;13(10):2315-27. doi: 10.1158/1535-7163.MCT-14-0258. Epub 2014 Jul 22.
• [549] Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012 Jul;2(7):591-7. doi: 10.1158/2159-8290.CD-12-0028. Epub 2012 Jun 15.
• [550] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [551] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [552] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [553] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [554] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [555] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [556] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [557] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [558] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [559] Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radic Biol Med. 2019 Feb 1;131:225-236. doi: 10.1016/j.freeradbiomed.2018.12.008. Epub 2018 Dec 11.
• [560] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [561] Lon protease and eiF2 are involved in acute, but not prolonged, antiretroviral induced stress response in HepG2 cells. Chem Biol Interact. 2016 May 25;252:82-6. doi: 10.1016/j.cbi.2016.03.021. Epub 2016 Apr 1.
• [562] Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. J Cell Biochem. 2008 May 1;104(1):38-50. doi: 10.1002/jcb.21597.
• [563] Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci. 2003 Oct;94(10):886-93.
• [564] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [565] Synergistic promotion of breast cancer cells death by targeting molecular chaperone GRP78 and heat shock protein 70. J Cell Mol Med. 2009 Nov-Dec;13(11-12):4540-50. doi: 10.1111/j.1582-4934.2008.00575.x.
• [566] Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol. 2002 Jul 31;35(4):377-83. doi: 10.5483/bmbrep.2002.35.4.377.
• [567] Intracellular mobility and nuclear trafficking of the stress-activated kinase JNK1 are impeded by hyperosmotic stress. Biochim Biophys Acta. 2014 Feb;1843(2):253-64. doi: 10.1016/j.bbamcr.2013.10.017. Epub 2013 Nov 1.
• [568] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [569] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [570] [Indomethacin-induced HL-60 leukemic cell apoptosis and the activation of C-jun NH2- terminal kinase signal transduction pathway]. Hunan Yi Ke Da Xue Xue Bao. 2003 Dec;28(6):557-62.
• [571] Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells. J Signal Transduct. 2012;2012:204236. doi: 10.1155/2012/204236. Epub 2012 Oct 9.
• [572] Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007 May;78(5):417-31. doi: 10.1111/j.1600-0609.2007.00835.x.
• [573] Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.
• [574] Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
• [575] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [576] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [577] A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2015 Jan;143(1):147-55. doi: 10.1093/toxsci/kfu215. Epub 2014 Oct 10.
• [578] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [579] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [580] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [581] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [582] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [583] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [584] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [585] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [586] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [587] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [588] The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019 Sep 1;310:108688. doi: 10.1016/j.cbi.2019.06.001. Epub 2019 Jun 4.
• [589] Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
• [590] Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
• [591] Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010 Oct 6;188(1):75-85. doi: 10.1016/j.cbi.2010.06.001. Epub 2010 Jun 9.
• [592] Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003 May 16;278(20):18092-100. doi: 10.1074/jbc.M300265200. Epub 2003 Mar 13.
• [593] TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol. 2011 Feb;223(3):378-89. doi: 10.1002/path.2797. Epub 2010 Oct 29.
• [594] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [595] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [596] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [597] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [598] A model to identify novel targets involved in oxidative stress-induced apoptosis in human lung epithelial cells by RNA interference. Toxicol In Vitro. 2010 Feb;24(1):310-8. doi: 10.1016/j.tiv.2009.08.008. Epub 2009 Aug 23.
• [599] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [600] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [601] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [602] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [603] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [604] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [605] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [606] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [607] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [608] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [609] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [610] CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
• [611] Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
• [612] Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. Inflamm Res. 2021 May;70(5):543-552. doi: 10.1007/s00011-021-01457-y. Epub 2021 Apr 13.
• [613] Dexmedetomidine protects against Ropivacaine-induced neuronal pyroptosis via the Nrf2/HO-1 pathway. J Toxicol Sci. 2023;48(3):139-148. doi: 10.2131/jts.48.139.
• [614] The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
• [615] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [616] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [617] Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
• [618] Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
• [619] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [620] Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
• [621] Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
• [622] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [623] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [624] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [625] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [626] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
• [627] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [628] Inhibition of phosphatidylinostol 3-kinase uncouples H2O2-induced senescent phenotype and cell cycle arrest in normal human diploid fibroblasts. Exp Cell Res. 2004 Aug 1;298(1):188-96. doi: 10.1016/j.yexcr.2004.04.012.
• [629] Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
• [630] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [631] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [632] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [633] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [634] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [635] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [636] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [637] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [638] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [639] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [640] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [641] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [642] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [643] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [644] Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
• [645] Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
• [646] Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. Cell Chem Biol. 2019 Mar 21;26(3):366-377.e12. doi: 10.1016/j.chembiol.2018.11.013. Epub 2019 Jan 17.
• [647] Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
• [648] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [649] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [650] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [651] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [652] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [653] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [654] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [655] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [656] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [657] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [658] Madecassoside ameliorates cisplatin-induced nephrotoxicity by inhibiting activation of the mitogen activated protein kinase pathway. Environ Toxicol. 2023 Jul;38(7):1473-1483. doi: 10.1002/tox.23777. Epub 2023 Apr 23.
• [659] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [660] Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009 Feb 27;256(3):183-90. doi: 10.1016/j.tox.2008.11.016. Epub 2008 Nov 28.
• [661] Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: Involvement of p38. Chem Biol Interact. 2012 Jan 25;195(2):154-64.
• [662] Arsenic trioxide promotes ERK1/2-mediated phosphorylation and degradation of BIM(EL) to attenuate apoptosis in BEAS-2B cells. Chem Biol Interact. 2023 Jan 5;369:110304. doi: 10.1016/j.cbi.2022.110304. Epub 2022 Dec 10.
• [663] Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.
• [664] Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol. 2012 May 1;83(9):1172-82. doi: 10.1016/j.bcp.2012.01.017. Epub 2012 Jan 21.
• [665] Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis. 2007 Jan;12(1):195-209. doi: 10.1007/s10495-006-0527-5.
• [666] Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos. 2006 Feb;34(2):296-304. doi: 10.1124/dmd.105.005280. Epub 2005 Nov 9.
• [667] Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol. 2000 Dec;131(8):1577-83.
• [668] Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl). 2002 Feb;115(2):280-5.
• [669] Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis. 2001 Sep;22(9):1393-7. doi: 10.1093/carcin/22.9.1393.
• [670] AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia. Chem Biol Interact. 2020 Jan 5;315:108888. doi: 10.1016/j.cbi.2019.108888. Epub 2019 Nov 2.
• [671] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [672] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [673] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [674] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [675] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [676] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [677] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [678] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [679] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
• [680] Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20.
• [681] Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
• [682] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [683] Down regulation of N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to induce apoptosis of human hepatocarcinoma cells. Mol Cell Biochem. 2006 Mar;284(1-2):103-10. doi: 10.1007/s11010-005-9022-5. Epub 2006 Jan 13.
• [684] Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
• [685] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [686] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [687] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [688] Tea polyphenols direct Bmal1-driven ameliorating of the redox imbalance and mitochondrial dysfunction in hepatocytes. Food Chem Toxicol. 2018 Dec;122:181-193.
• [689] Mitophagy inhibits proliferation by decreasing cyclooxygenase-2 (COX-2) in arsenic trioxide-treated HepG2 cells. Environ Toxicol Pharmacol. 2016 Jul;45:212-21.
• [690] Capsaicin inhibits the migration, invasion and EMT of renal cancer cells by inducing AMPK/mTOR-mediated autophagy. Chem Biol Interact. 2022 Oct 1;366:110043. doi: 10.1016/j.cbi.2022.110043. Epub 2022 Aug 28.
• [691] PPAR- activation attenuates deltamethrin-induced apoptosis by regulating cytosolic PINK1 and inhibiting mitochondrial dysfunction. Toxicol Lett. 2016 Oct 17;260:8-17. doi: 10.1016/j.toxlet.2016.08.016. Epub 2016 Aug 21.
• [692] Melatonin ameliorates acute lung injury caused by paraquat poisoning by promoting PINK1 and BNIP3 expression. Toxicology. 2023 May 15;490:153506. doi: 10.1016/j.tox.2023.153506. Epub 2023 Apr 5.
• [693] Endoplasmic Reticulum Stress Induction and ERK1/2 Activation Contribute to Nefazodone-Induced Toxicity in Hepatic Cells. Toxicol Sci. 2016 Dec;154(2):368-380. doi: 10.1093/toxsci/kfw173. Epub 2016 Sep 9.
• [694] [Mechanism of arsenic trioxide induced apoptosis in cultured human lens epithelium cells]. Zhonghua Yan Ke Za Zhi. 2008 Oct;44(10):916-20.
• [695] Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 2007 Feb 1;67(3):1262-9. doi: 10.1158/0008-5472.CAN-06-1794.
• [696] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [697] Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
• [698] Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway. Biochem Biophys Res Commun. 2018 Jan 29;496(1):167-175. doi: 10.1016/j.bbrc.2018.01.018. Epub 2018 Jan 4.
• [699] TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
• [700] Inhibition of autophagy enhances Hydroquinone-induced TK6 cell death. Toxicol In Vitro. 2017 Jun;41:123-132. doi: 10.1016/j.tiv.2017.02.024. Epub 2017 Mar 2.
• [701] Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe. 2009 Sep 17;6(3):231-43. doi: 10.1016/j.chom.2009.08.004.
• [702] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [703] A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
• [704] Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
• [705] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [706] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [707] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [708] Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
• [709] Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G731-8. doi: 10.1152/ajpgi.00150.2005. Epub 2005 Jun 23.
• [710] Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer. Cell Death Dis. 2019 Nov 7;10(11):846. doi: 10.1038/s41419-019-2001-7.
• [711] Effect of quercetin on apoptosis of PANC-1 cells. J Korean Surg Soc. 2013 Dec;85(6):249-60. doi: 10.4174/jkss.2013.85.6.249. Epub 2013 Nov 26.
• [712] BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2843-52.
• [713] The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study. Toxicol In Vitro. 2020 Aug;66:104884. doi: 10.1016/j.tiv.2020.104884. Epub 2020 May 8.
• [714] Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer. 2011 Jul 12;105(2):221-30. doi: 10.1038/bjc.2011.229.
• [715] Anti-cancer properties of glucosamine-hydrochloride in YD-8 human oral cancer cells: Induction of the caspase-dependent apoptosis and down-regulation of HIF-1. Toxicol In Vitro. 2012 Feb;26(1):42-50. doi: 10.1016/j.tiv.2011.10.005. Epub 2011 Oct 13.
• [716] Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
• [717] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [718] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [719] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [720] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [721] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [722] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [723] Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer. 2015 May 14;14:103. doi: 10.1186/s12943-015-0367-4.
• [724] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [725] Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. Brain Res Mol Brain Res. 2001 Feb 19;87(1):100-8. doi: 10.1016/s0165-3806(00)00154-1.
• [726] Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
• [727] The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:44-9. doi: 10.1046/j.1365-2036.2000.014s1044.x.
• [728] Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer. 2007 Oct 15;121(8):1697-704. doi: 10.1002/ijc.22867.
• [729] Regulation of keratinocyte growth factor and scatter factor in cyclosporin-induced gingival overgrowth. J Oral Pathol Med. 2004 Aug;33(7):391-7. doi: 10.1111/j.1600-0714.2004.00223.x.
• [730] Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett. 2015 Jun 15;235(3):189-98. doi: 10.1016/j.toxlet.2015.04.005. Epub 2015 Apr 9.
• [731] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [732] Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
• [733] Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
• [734] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [735] Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
• [736] Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
• [737] Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
• [738] Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28.
• [739] Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006 Nov 15;12(22):6817-25. doi: 10.1158/1078-0432.CCR-06-1354.
• [740] HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. Curr Issues Mol Biol. 2023 Aug 23;45(9):7011-7026. doi: 10.3390/cimb45090443.
• [741] Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.
• [742] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [743] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [744] SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver. Mol Pharmacol. 2015 Apr;87(4):674-82. doi: 10.1124/mol.114.097287. Epub 2015 Jan 27.
• [745] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.